June 27, 2014 Approval Letter - FluLaval
Our STN: BL 125163/319
ID Biomedical Corporation of Quebec
Attention: LaDonna F. Nugent, M.S.
2301 Renaissance Boulevard, Bldg 510
P.O. Box 61540
King of Prussia, PA 19406-2772
Dear Ms. Nugent:
We have approved your request to supplement your biologics license application for Influenza Vaccine (FluLaval®/FluLaval® Quadrivalent) manufactured at your Sainte-Foy, Quebec, Canada, facility, to include the 2014-2015 United States formulation.
Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. In addition, please submit three original paper copies for carton and container final printed labeling. All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h and FDA Form 2567 as appropriate.
You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Advertising and Promotional Labeling Branch at the following address:
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).
Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.
We will include information contained in the above-referenced supplement in your biologics license application file.
Jerry P. Weir, Ph.D.
Division of Viral Products
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research